IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study.

IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study. Haematologica. 2019 Oct 03;: Authors: Rotbain EC, Frederiksen H, Hjalgrim H, Rostgaard K, Jakupsdottir Egholm G, Zahedi B, Poulsen CB, Enggaard L, da Cunha-Bang C, Niemann CU Abstract Patients with chronic lymphocytic leukemia and immunoglobulin heavy-chain variable region gene unmutated status have inferior survival from time of treatment in clinical studies. We assessed real-world outcomes based on mutational status and treatment regimen in a nationwide population-based cohort, comprising all 4135 patients from the Danish chronic lymphocytic leukemia registry diagnosed between 2008 and 2017. In total, 850 patients with known mutational status received treatment: 42% of patients received intensive chemoimmunotherapy treatment consisting of fludarabine, cyclophosphamide plus rituximab, or bendamustine plus rituximab; 27% received chlorambucil in combination with anti-CD20 antibodies or as monotherapy, and 31% received other, less common, treatments. No difference in overall survival from time of first treatment according to mutational status was observed, while treatment-free survival from start of first treatment was inferior for unmutated patients. The median treatment-free survival was 2.5 years for patients treated with chlorambucil plus anti-CD20, and 1 year for chlorambucil monotherapy. T...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research